Navigation Links
Boston Scientific to Acquire Vessix Vascular

LAGUNA HILLS, Calif., Nov. 8, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has signed a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX). The acquisition is expected to close by the end of November 2012. 

The agreement calls for an upfront payment of $125 million, plus $300 million in additional clinical and sales-based milestones aggregating a maximum value of the transaction of $425 million.

"Hypertension is a major global healthcare challenge, affecting more than one billion people worldwide," said Mike Mahoney, president and chief executive officer at Boston Scientific. "Renal denervation represents a potential breakthrough therapy for the treatment of uncontrolled hypertension and is an important part of the Boston Scientific growth strategy. The acquisition of Vessix Vascular adds a second generation, highly differentiated technology to our hypertension strategy while accelerating our entry into what we expect to be a multi-billion dollar market by 2020."

Hypertension is the leading attributable cause of death worldwide.  Despite the widespread availability of antihypertensive medications, the blood pressure of many patients remains high and uncontrolled.  Renal denervation is an emerging, catheter-based therapy for medication-resistant hypertension that uses radiofrequency energy to disrupt the renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.  Renal denervation has been demonstrated in published clinical studies to significantly reduce systolic blood pressure.

Raymond W. Cohen, chief executive officer at Vessix Vascular said, "We are confident that the combination of the Vessix Vascular renal denervation technology with the Boston Scientific broad global clinical and commercial scale will result in a new standard for the treatment of uncontrolled hypertension."

The Vessix Vascular V2 Renal Denervation System™ has received CE Mark in Europe and TGA approval in Australia. Vessix Vascular has initiated the REDUCE-HTN post-market surveillance study and expects to initiate a full launch of the product in CE Mark countries in 2013. 

"The Vessix System offers the potential for a significant step forward in the treatment of uncontrolled hypertension," said Prof. Horst Sievert, M.D., Ph.D., Director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital, in Frankfurt, Germany.  "In my experience, the system offers ease of use, faster treatment times with decreased patient discomfort and an intuitive approach to renal denervation that leverages the expertise of the interventionalist with balloon catheter technology."

"We expect that hypertension therapies will be a key growth driver for Boston Scientific going forward," said Jeff Mirviss, president of the Peripheral Interventions business for Boston Scientific. "We believe the Vessix Vascular Renal Denervation System will position us for leadership in this important market.  We look forward to offering this technology to help patients better control their blood pressure, which also may lead to reduced healthcare costs associated with uncontrolled hypertension."

Upon completion of the acquisition, Vessix Vascular will become part of the Peripheral Interventions business at Boston Scientific.  The portfolio of this business includes products that treat vascular system blockages in areas such as the carotid and renal arteries and the lower extremities.

The V2 Renal Denervation System is an investigational device and not available for use or sale in the United States.

About Vessix Vascular
Founded in 2003, Vessix is a private company backed by world-class European and U.S. venture capital firms including NeoMed Management, Edmond de Rothschild Investment Partners, Fjord Invest, OrbiMed Advisors LLC and Christopher Weil & Company. For more information, please visit

About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit:

Matt Clawson orLen Hall (Media) Allen & Caron Inc  

SOURCE Vessix Vascular, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
6. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
9. Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators
10. Boston Scientific Closes Cameron Health Acquisition
11. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
Post Your Comments:
(Date:11/24/2015)... LONDON , November 24, 2015 ... PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and ... areas are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ...
(Date:11/24/2015)...  Enova Illumination is pleased to announce a new ... to combine their world class camera and ... of medical visualization: Enova is the first manufacturer of ... and Novocam is the manufacturer of HD ... most powerful battery-operated LED headlight with high-quality point-of-view video ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Abaxis, ... manufacturing point-of-care instruments and consumables for the medical, research, ... Taylor , Chief Financial Officer, will present at the ... Tuesday, December 1, 2015 at 11:30 a.m. ET. The ... Palace in New York City . ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association of ... local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, the ... that inspires people to collaborate in improving their local communities and help give ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the Ron ... designed to yield insights into how to detect and treat pancreatic cancer (PC). ... from small, non-coding RNA molecules (ncRNA), genetic material that is present in the blood ...
(Date:11/24/2015)... ... , ... Dr. Rodney E. Willey , has answered a new calling – to relieve ... provides treatment for snoring and sleep apnea through oral appliance therapy. He ... Disorders in the US, one of four in the Illinois area. , Dr. Willey’s ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading ... driven by social media and the generosity of people around the world. On December ... media networks to give – and share the personal stories behind those gifts. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Robert Yeager ... Report . Throughout the past year there have been multiple breakthroughs and challenges as ... this transition, PharmMD has enabled their customers and partners to stay ahead of the ...
Breaking Medicine News(10 mins):